A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Inclusion Criteria:

• Low Grade Glioma & Low-Grade Glioma Extension: a relapsed or progressive LGG withdocumented known activating BRAF alteration.

• Advanced Solid Tumor: locally advanced or metastatic solid tumor with documentedknown or expected to be activating RAF fusion.

• Participants must have histopathologic verification of malignancy at either originaldiagnosis or relapse.

• Must have received at least one line of prior systemic therapy and have documentedevidence of radiographic progression.

• Must have at least 1 measurable lesion as defined by RANO (Arms 1 & 2) or RECISTv1.1 (Arm 3) criteria

Exclusion Criteria:

• Participant's tumor has additional previously-known activating molecularalterations.

• Participant has symptoms of without radiographically recurrent or radiographicallyprogressive disease.

• Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testingor current diagnostic criteria.

Other inclusion/exclusion criteria as stipulated by protocol may apply